Eli Lilly Revenue 2010-2022 | LLY

Eli Lilly annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Eli Lilly revenue for the quarter ending March 31, 2022 was $7.810B, a 14.76% increase year-over-year.
  • Eli Lilly revenue for the twelve months ending March 31, 2022 was $29.323B, a 15.06% increase year-over-year.
  • Eli Lilly annual revenue for 2021 was $28.318B, a 15.4% increase from 2020.
  • Eli Lilly annual revenue for 2020 was $24.54B, a 9.95% increase from 2019.
  • Eli Lilly annual revenue for 2019 was $22.32B, a 3.84% increase from 2018.
Eli Lilly Annual Revenue
(Millions of US $)
2021 $28,318
2020 $24,540
2019 $22,320
2018 $21,493
2017 $19,974
2016 $21,222
2015 $19,959
2014 $19,616
2013 $23,113
2012 $22,603
2011 $24,287
2010 $23,076
2009 $21,836
Eli Lilly Quarterly Revenue
(Millions of US $)
2022-03-31 $7,810
2021-12-31 $8,000
2021-09-30 $6,773
2021-06-30 $6,740
2021-03-31 $6,806
2020-12-31 $7,440
2020-09-30 $5,741
2020-06-30 $5,499
2020-03-31 $5,860
2019-12-31 $6,114
2019-09-30 $5,477
2019-06-30 $5,637
2019-03-31 $5,092
2018-12-31 $5,638
2018-09-30 $5,307
2018-06-30 $5,585
2018-03-31 $4,964
2017-12-31 $3,263
2017-09-30 $5,658
2017-06-30 $5,824
2017-03-31 $5,228
2016-12-31 $5,761
2016-09-30 $5,192
2016-06-30 $5,405
2016-03-31 $4,865
2015-12-31 $5,376
2015-09-30 $4,960
2015-06-30 $4,979
2015-03-31 $4,645
2014-12-31 $5,121
2014-09-30 $4,876
2014-06-30 $4,936
2014-03-31 $4,683
2013-12-31 $5,809
2013-09-30 $5,773
2013-06-30 $5,930
2013-03-31 $5,602
2012-12-31 $5,957
2012-09-30 $5,443
2012-06-30 $5,601
2012-03-31 $5,602
2011-12-31 $6,047
2011-09-30 $6,148
2011-06-30 $6,253
2011-03-31 $5,839
2010-12-31 $6,187
2010-09-30 $5,655
2010-06-30 $5,749
2010-03-31 $5,486
2009-12-31 $5,934
2009-09-30 $5,562
2009-06-30 $5,293
2009-03-31 $5,047
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $310.873B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $468.758B 18.03
Pfizer (PFE) United States $289.747B 10.11
AbbVie (ABBV) United States $272.011B 11.92
Merck (MRK) United States $234.269B 13.23
Novartis AG (NVS) Switzerland $186.478B 13.57
GlaxoSmithKline (GSK) United Kingdom $110.060B 12.85
Novo Nordisk (NVO) Denmark $0.000B 33.11